KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationCost of RevenueEBIATLeasesLong-Term Debt IssuancesOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - NetReceivables - OtherShares Repurchased
Ratios

Emergent BioSolutions (EBS) Receivables Refunds (2016 - 2020)

Emergent BioSolutions' Receivables Refunds history spans 11 years, with the latest figure at $10.2 million for Q1 2020.

  • For Q1 2020, Receivables Refunds changed N/A year-over-year to $10.2 million; the TTM value through Mar 2020 reached $10.2 million, changed N/A, while the annual FY2019 figure was $4.6 million, 46.51% down from the prior year.
  • Receivables Refunds reached $10.2 million in Q1 2020 per EBS's latest filing, up from $4.6 million in the prior quarter.
  • In the past five years, Receivables Refunds ranged from a high of $11.8 million in Q3 2016 to a low of $2.4 million in Q4 2017.
  • Average Receivables Refunds over 5 years is $7.3 million, with a median of $7.0 million recorded in 2018.
  • Peak YoY movement for Receivables Refunds: crashed 77.85% in 2016, then surged 258.33% in 2018.
  • A 5-year view of Receivables Refunds shows it stood at $10.0 million in 2016, then plummeted by 75.99% to $2.4 million in 2017, then soared by 258.33% to $8.6 million in 2018, then tumbled by 46.51% to $4.6 million in 2019, then soared by 121.74% to $10.2 million in 2020.
  • Per Business Quant, the three most recent readings for EBS's Receivables Refunds are $10.2 million (Q1 2020), $4.6 million (Q4 2019), and $8.6 million (Q4 2018).